This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HEBIG (EU), Hepatitis B Immune Globulin (Human) Intravenous
Description: BioMedTracker has separate drug profiles for the intravenous and intramuscular formulations of Nabi-HB. Please also see NABI-HB (IM).
Nabi-HB Intravenous is a sterile solution of human antibodies to HBV formulated and packaged specifically for intravenous use.
Deal Structure: In September 2007, Nabi Biopharmaceuticals announced that it had entered into a definitive agreement with Biotest AG to sell the Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corporation for $185 million. The acquisition of Biologics SBU's products includes Nabi-HB, Civacir, and Altastaph. Nabi will retain its Pharmaceuticals strategic business unit assets, including NicVAX and its investigational StaphVAX programs.
In December 2007, Biotest completed its acquisition of Nabi's Biologics strategic business unit.
Nabi-HB (IV) News
Pink Sheet Nabi Nabi-HB
Additional information available to subscribers only: